-transparent.png){kind=logo}
Eltoprazine. HCl belongs to a new class of psychotropic drug, the serenics. The dose-proportionality and pharmacokinetics of eltoprazine HCl has been investigated after single oral doses of 5, 10, 20 mg (18 subjects) and 30 mg (12 subjects) in a partly randomized, cross-over design. Eltoprazine was well tolerated and there were no relevant changes in safety parameters. All subjects showed irregular plasma-concentration-time profiles, some subjects demonstrating secondary peaks. The mean half-life was calculated to be about 6.5 h. The renal excretion of eltoprazine was characterized by net tubular secretion. AUC, peak plasma concentrations and the amount excreted unchanged in the urine were linearly related to the dose. Renal clearance and t1/2 were independent of dose. Thus, eltoprazine HCl was well tolerated orally and exhibited a linear pharmacokinetic profile.
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
December 1990,
British journal of clinical pharmacology,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
January 2002,
British journal of clinical pharmacology,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
June 2001,
Journal of clinical pharmacology,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
January 1990,
Drug metabolism and drug interactions,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
December 1992,
Biopharmaceutics & drug disposition,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
December 2010,
Archives of drug information,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
July 1984,
Journal of clinical pharmacology,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
March 2016,
Drug research,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
April 1990,
Journal of clinical pharmacology,
M H de Vries, and
P de Koning, and
H L Floot, and
A Grahnén, and
S A Eckernäs, and
M Raghoebar, and
B Dahlström, and
L Ekman
January 2002,
Clinical pharmacokinetics,
